$0.22
+0.02 (+10.06%)
Open$0.20
Previous Close$0.20
Day High$0.22
Day Low$0.19
52W High$32.39
52W Low$17.11
Volume—
Avg Volume383.3K
Market Cap7.85M
P/E Ratio21.71
EPS$1.38
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+17,504.5% upside
Current
$0.22
$0.22
Target
$38.73
$38.73
$26.34
$38.73 avg
$46.19
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.03M | 1.08M | 955.9K |
| Net Income | -22,361 | -31,787 | -25,174 |
| Profit Margin | -2.2% | -2.9% | -2.6% |
| EBITDA | -38,355 | -35,389 | -33,870 |
| Free Cash Flow | -18,843 | -19,077 | -22,857 |
| Rev Growth | +0.6% | -3.8% | +4.7% |
| Debt/Equity | 0.84 | 0.93 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |